Kodiak Sciences Inc. (KOD)
NASDAQ: KOD · Real-Time Price · USD
8.84
+0.59 (7.15%)
At close: Jul 25, 2025, 4:00 PM
8.95
+0.11 (1.22%)
After-hours: Jul 25, 2025, 7:55 PM EDT
Kodiak Sciences Employees
Kodiak Sciences had 109 employees as of December 31, 2024. The number of employees decreased by 2 or -1.80% compared to the previous year.
Employees
109
Change (1Y)
-2
Growth (1Y)
-1.80%
Revenue / Employee
n/a
Profits / Employee
-$1,748,890
Market Cap
465.25M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 109 | -2 | -1.80% |
Dec 31, 2023 | 111 | -1 | -0.89% |
Dec 31, 2022 | 112 | 19 | 20.43% |
Dec 31, 2021 | 93 | 21 | 29.17% |
Dec 31, 2020 | 72 | 33 | 84.62% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
KOD News
- 16 days ago - Kodiak Sciences to Host Investor R&D Day on July 16, 2025 - PRNewsWire
- 4 weeks ago - Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society - PRNewsWire
- 2 months ago - Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference - PRNewsWire
- 2 months ago - Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results - PRNewsWire
- 3 months ago - Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases - PRNewsWire
- 4 months ago - Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 4 months ago - Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy - PRNewsWire
- 5 months ago - Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders - Seeking Alpha